Avacta Therapeutics (AIM: AVCT) has reported strong progress across its oncology pipeline in the first half of 2026, highlighting advances in both its clinical programmes and balance sheet ahead of today’s Annual General Meeting.
Chief executive Christina Coughlin said recent data continue to validate Avacta’s proprietary pre|CISION® platform, which is designed to activate cancer treatments specifically within tumours, potentially improving efficacy while reducing side effects.
The company’s second-generation programme, AVA6103, reached a significant milestone after receiving regulatory clearance in January and dosing its first patient in the Phase I FOCUS-01 trial during March. Patient recruitment is continuing, with initial clinical data expected in the second half of 2026. Preclinical studies presented during the year have also demonstrated favourable comparisons with established antibody-drug conjugates including Enhertu and Datroway.
Meanwhile, Avacta’s first-generation candidate AVA6000 delivered encouraging clinical results at the American Society of Clinical Oncology meeting, particularly in salivary gland cancers. Regulators have since lifted the lifetime maximum dose restriction following positive cardiac safety data and agreement on future dose selection.
The third-generation AVA6207 programme also continued to advance, with new data supporting the company’s dual-payload technology and ongoing growth in its intellectual property portfolio. Management expects payload and clinical candidate selection during the second half of the year.
Financially, Avacta strengthened its position through two successful fundraisings in 2026. A £10 million oversubscribed placing completed in March extended the company’s cash runway into early 2027, while a further £9 million fundraising in June enabled a reduction in outstanding convertible bond debt and further strengthened the balance sheet. Combined with previous financings, the company has raised £41.5 million over the past 18 months.
The board was also strengthened with Richard Hughes formally taking up the role of Non-Executive Chairman, while a new Deputy Chairman and Senior Independent Director is expected to be appointed shortly.
Looking ahead, investors can expect several important catalysts during the second half of 2026, including the first clinical data from AVA6103, additional AVA6000 results from ongoing studies, progress within the AVA6207 programme and continued discussions regarding potential partnering opportunities across Avacta’s pipeline. The company said talks remain active with multiple parties interested in its first, second and third-generation assets.
